| Date | Title | | | 12/21/11 | LabCorp(R) Enters into New Credit Facility Totaling $1.0 Billion| BURLINGTON, N.C., Dec 21, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced that it has entered into a new senior
unsecured credit facility totaling $1.0 billion. Bank of America, N.A.
will act as Administrative Agent and Barclays Capital will serve as
Syndication Agent for a group of financial institutions providing the
facility. The new facility consists of a five-year Revolving Facility in
... |
|  | | 12/16/11 | LabCorp Successfully Completes Acquisition of Orchid Cellmark Inc.| BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 16, 2011--
Laboratory Corporation of America® Holdings (NYSE: LH) today announced
the successful completion of the previously announced subsequent
offering period for the cash tender offer by its wholly owned
subsidiary, OCM Acquisition Corp. (“OCM”), for all outstanding shares of
common stock of Orchid Cellmark Inc. (NASDAQ: ORCH) (“Orchid Cellmark”).
As of 4:00 p.m., New York City time, on December 15, 2011, ... |
| | | 12/12/11 | LabCorp Successfully Completes Tender Offer for Orchid Cellmark and Commences Subsequent Offering Period to Allow for Additional Tenders| BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 12, 2011--
Laboratory Corporation of America® Holdings (NYSE: LH) today announced
the successful completion of the cash tender offer by its wholly owned
subsidiary, OCM Acquisition Corp., for all outstanding shares of common
stock of Orchid Cellmark Inc. (NASDAQ: ORCH). The initial offer period
for the tender offer expired at 5:00 p.m., New York City time, on
December 9, 2011.
The depositary for ... |
| | | 12/08/11 | U.S. Federal Trade Commission Approves LabCorp’s Acquisition of Orchid Cellmark| BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 8, 2011--
Laboratory Corporation of America® Holdings (NYSE: LH) today
announced that it has reached an agreement with the U.S. Federal Trade
Commission allowing LabCorp to complete its acquisition of Orchid
Cellmark Inc (NASDAQ: ORCH). Under the terms of the proposed consent
decree that was accepted by the FTC for public comment, LabCorp is
required to divest certain assets of Orchid Cellmark’s U.S. government... |
| | | 12/01/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 1, 2011--
Laboratory Corporation of America® Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
December 9, 2011, LabCorp’s previously announced cash tender offer for
all outstanding shares of the common stock of Orchid Cellmark Inc.
(NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the
Federal Trade Commission, or the FTC, for additional informa... |
| | | 11/15/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 15, 2011--
Laboratory Corporation of America® Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
November 30, 2011 LabCorp’s previously announced cash tender offer for
all outstanding shares of the common stock of Orchid Cellmark Inc.
(NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the
Federal Trade Commission, or the FTC, for additional inform... |
| | | 11/07/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Nov 07, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
November 14, 2011 LabCorp's previously announced cash tender offer for
all outstanding shares of the common stock of Orchid Cellmark Inc.
(NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the
Federal Trade Commission, or the FTC, for additional information ... |
| | | 11/03/11 | LabCorp is Scheduled to Present at the Credit Suisse 2011 Healthcare Conference| BURLINGTON, N.C., Nov 03, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced that William B. (Brad) Hayes, Executive Vice
President and Chief Financial Officer, is scheduled to speak at the
Credit Suisse 2011 Healthcare Conference in Phoenix, AZ. LabCorp's
presentation is planned for Thursday, November 10, 2011 at 10:30 a.m.
(Mountain Standard Time).
A live audio webcast of the presentation wil... |
| | | 10/20/11 | Laboratory Corporation of America(R) Holdings Announces Third Quarter 2011 Results| Strong Revenue Growth Drives EPS of $1.31 and Adjusted EPS
Excluding Amortization of $1.61
BURLINGTON, N.C., Oct 20, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced results for the quarter ended September 30,
2011.
Third Quarter Results
Net earnings were $134.3 million and earnings per diluted share (EPS)
were $1.31 in the third quarter of 2011. Non-GAAP earnings per diluted
share, exc... |
| | | 10/10/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Oct 10, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
November 4, 2011 LabCorp's previously announced cash tender offer for
all outstanding shares of the common stock of Orchid Cellmark Inc.
(NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the
Federal Trade Commission, or the FTC, for additional information u... |
| | | 10/06/11 | Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Oct 06, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today that its Zero Coupon Convertible Subordinated
Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.
The Zero Coupon Notes are convertible into cash and Common Stock of
LabCorp, if any, subject to the terms of the Zero Coupon Notes and the
Indenture, dated as of October 24, 2006 between LabCorp and The Bank of... |
| | | 10/03/11 | LabCorp To Offer a New Companion Diagnostic for Non-Small Cell Lung Cancer| BURLINGTON, N.C., Oct 03, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today the nationwide availability of a new
FDA-approved companion diagnostic for lung cancer patients.
The drug XALKORI(R), available from Pfizer, and Abbott
Molecular's Vysis ALK Break Apart FISH Probe companion diagnostic test
were simultaneously approved by the FDA on August 26, 2011 for use in
patients with advanced ALK-... |
| | | 09/13/11 | LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest| BURLINGTON, N.C., Sep 13, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today that for the period of September 12, 2011 to
March 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021
(Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes,
accrue contingent cash interest at a rate of no less than 0.125% of the
average market price of a Zero Coupon Note for the five trading... |
| | | 09/12/11 | LabCorp to Offer a New Companion Diagnostic for Melanoma| BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today the nationwide availability of a new
FDA-approved diagnostic for melanoma patients.
The drug ZelborafTM and the cobas(R) 4800 BRAF V600 Mutation
Test companion diagnostic, both from Roche, were approved by the FDA on
August 17 for use in patients with inoperable or metastatic melanoma
with the BRAFV600E gene mutation. ... |
| | | 09/12/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
October 7, 2011 LabCorp's previously announced cash tender offer for all
outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ:
ORCH). On May 17, 2011, LabCorp received a request from the Federal
Trade Commission, or the FTC, for additional information un... |
| | | 09/12/11 | Laboratory Corporation of America(R) Holdings Announces Results of Offer to Purchase Its Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today the results of its offer (the "Offer") to
purchase its Zero Coupon Convertible Subordinated Notes due 2021 (the
"Notes") for cash. The Offer was required pursuant to the terms of the
indenture under which the Notes were issued and was first announced on
August 11, 2011.
LabCorp has been advised by the paying agent, The... |
| | | 09/08/11 | LabCorp Extends Agreement with UnitedHealthcare| BURLINGTON, N.C., Sep 08, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today that it has extended the term of its
agreement with UnitedHealthcare Insurance Company (UnitedHealthcare), an
affiliate of UnitedHealth Group Incorporated (NYSE: UNH) for an
additional two years. The agreement, which was effective January 1,
2007, will now continue through the end of 2018. Under the terms of the
agr... |
| | | 09/06/11 | LabCorp is Scheduled to Present at the Bank of America Merrill Lynch Global Healthcare Conference| BURLINGTON, N.C., Sep 06, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced that David P. King, Chairman and Chief
Executive Officer, is scheduled to speak at the Bank of America Merrill
Lynch Global Healthcare Conference in London, United Kingdom. LabCorp's
presentation is planned for Wednesday, September 14, 2011.
About LabCorp(R)
Laboratory Corporation of America(R) Holdings, an S&P 500
co... |
| | | 08/25/11 | LabCorp Introduces HCV Resistance Testing through Monogram Biosciences with the Launch of HCV GenoSure(R) NS3/4A| BURLINGTON, N.C., Aug 25, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) announced today the nationwide availability of a nucleic acid
sequencing assay that reports NS3 and NS4A mutations and NS3 associated
resistance to the recently approved hepatitis C virus (HCV) protease
inhibitors, adding to LabCorp's suite of HCV testing. Identification of
certain mutations may be useful to clinicians considering patient ... |
| | | 08/15/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Aug 15, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 5:00 p.m., New York City time, on
September 9, 2011 LabCorp's previously announced cash tender offer for
all outstanding shares of the common stock of Orchid Cellmark Inc.
(NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the
Federal Trade Commission, or the FTC, for additional information ... |
| | | 08/11/11 | Laboratory Corporation of America(R) Holdings Announces Commencement of Offer to Purchase Its Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Aug 11, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) ("LabCorp") announced today that it is notifying holders of its Zero Coupon Convertible Subordinated Notes due 2021 (the "Notes") that they have the right, pursuant to the terms of the Notes, to require LabCorp to purchase, on September 12, 2011, all or a portion of their Notes. The purchase price for the Notes is $819.54 per $1,000 principal amount at maturity of the Notes.
Holders who e... |
| | | 08/10/11 | LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute to Offer Specialized Biomarker and Assay Development Services| BURLINGTON, N.C., Aug 10, 2011 (BUSINESS WIRE) --Esoterix Clinical Trials Services, a division of Laboratory Corporation
of America(R) Holdings (LabCorp(R)) (NYSE: LH), today
announced a strategic alliance with the David H. Murdock Research
Institute (DHMRI) to provide its clients with access to enhanced assay
development services. Assays developed at DHMRI for contracted research
will be transferred to LabCorp Clinical Trials laboratories worldwide to
... |
| | | 07/21/11 | Laboratory Corporation of America(R) Holdings Announces Second Quarter 2011 Results| Strong Volume and Revenue Growth Drives Adjusted EPS Excluding
Amortization of $1.64
BURLINGTON, N.C., Jul 21, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced results for the quarter ended June 30, 2011.
Second Quarter Results
Net earnings were $122.9 million and earnings per diluted share (EPS)
were $1.20 in the second quarter of 2011. Earnings per diluted share,
excluding amortization, restr... |
| | | 07/18/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Jul 18, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on August 12, 2011, LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the Federal Trade Commission, or the FTC, for additional information under the Hart-Scott-Rodino Antitrust Im... |
| | | 07/01/11 | Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Jul 01, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.
The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee) a... |
| | | 06/16/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Jun 16, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on July 15, 2011, LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17, 2011, LabCorp received a request from the Federal Trade Commission, or the FTC, for additional information under the Hart-Scott-Rodino Antitrust Impr... |
| | | 06/02/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Jun 02, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 6:00 p.m., New York City time, on June
15, 2011, LabCorp's previously announced cash tender offer for all
outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ:
ORCH). On May 17, 2011, LabCorp received a request from the Federal
Trade Commission, or the FTC, for additional information und... |
| | | 06/01/11 | LabCorp Enters into Definitive Agreement to Acquire Clearstone Central Laboratories| BURLINGTON, N.C. & TORONTO, Jun 01, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today
announced that it has entered into a definitive agreement to acquire
Clearstone Central Laboratories, a leading global provider of central
laboratory services for late-stage clinical trials. The transaction,
which is subject to customary closing conditions, is expected to close
in the second quarter of 2011. Terms of the ag... |
| | | 05/18/11 | LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., May 18, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced
that LabCorp is extending until 6:00 p.m., New York City time, on June
1, 2011 LabCorp's previously announced cash tender offer for all
outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ:
ORCH). On May 17, 2011, LabCorp received a request from the Federal
Trade Commission, or the FTC, for additional information under... |
| | | 05/09/11 | LabCorp(R) Scheduled to Webcast Its Annual Meeting of Stockholders| BURLINGTON, N.C., May 09, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced that its Annual Meeting of Stockholders will
be webcast live beginning May 11, 2011 at 9:00 a.m. Eastern Time via the
Company Web site at www.labcorp.com.
An archived replay of the audio webcast will be available through June
11, 2011.
About LabCorp(R)
Laboratory Corporation of America(R) Holdings, an S&P 500
... |
| | | 05/05/11 | LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2011 Health Care Conference| BURLINGTON, N.C., May 05, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced that David P. King, Chairman and Chief
Executive Officer, is scheduled to speak at the Bank of America Merrill
Lynch 2011 Health Care Conference in Las Vegas, NV. LabCorp's
presentation is planned for Thursday, May 12, 2011 at 11:10 a.m. (PT).
A live audio webcast of the presentation will be available via the
Company W... |
| | | 04/21/11 | Laboratory Corporation of America(R) Holdings Announces First Quarter 2011 Results| Strong Revenue Growth Drives Adjusted EPS Excluding Amortization
of $1.52, Up 8.6%, and Operating Cash Flow of $215.3 Million
BURLINGTON, N.C., Apr 21, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today announced results for the quarter ended March 31, 2011.
These results include the operations of Genzyme Genetics, which the
Company acquired in the fourth quarter of 2010.
First Quarter Results
Net earnings w... |
| | | 04/19/11 | LabCorp Commences Cash Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.| BURLINGTON, N.C., Apr 19, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (NYSE:LH) today announced
the commencement of its cash tender offer for all outstanding shares of
the common stock of Orchid Cellmark Inc. (NASDAQ:ORCH) for $2.80 per
share. The tender offer is being made by OCM Acquisition Corp. a wholly
owned subsidiary of LabCorp, pursuant to an Offer to Purchase, dated
April 19, 2011. LabCorp and Orchid Cellmark previously an... |
| | | 04/06/11 | LabCorp Announces Definitive Agreement to Acquire Orchid Cellmark Inc.| Acquisition Price of $2.80 per Share in All Cash Transaction
BURLINGTON, N.C. & PRINCETON, N.J., Apr 06, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) and Orchid Cellmark Inc. (NASDAQ: ORCH), an international
provider of DNA testing services primarily for forensic and family
relationship applications, today announced that they have entered into a
definitive agreement and plan of merger under which LabCorp will acqu... |
| | | 04/04/11 | Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Apr 04, 2011 (BUSINESS WIRE) --Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH)
announced today that its Zero Coupon Convertible Subordinated Notes due
2021 (Zero Coupon Notes) may be converted as set forth below.
The Zero Coupon Notes are convertible into cash and Common Stock of
LabCorp, if any, subject to the terms of the Zero Coupon Notes and the
Indenture, dated as of October 24, 2006 between LabCorp and The Bank of
... |
| | | 03/14/11 | LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest| BURLINGTON, N.C., Mar 14, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2011 to September 11, 2011, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 9, 2011, in addition to t... |
| | | 03/09/11 | LabCorp is Scheduled to Present at the Barclays Capital 2011 Global Healthcare Conference| BURLINGTON, N.C., Mar 09, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2011 Global Healthcare Conference in Miami Beach, FL. LabCorp's presentation is planned for Wednesday, March 16, 2011 at 9:00 a.m. (Eastern Time).
A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and arch... |
| | | 02/23/11 | LabCorp is Scheduled to Speak at RBC Capital Markets' 2011 Healthcare Conference| BURLINGTON, N.C., Feb 23, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the RBC Capital Markets' 2011 Healthcare Conference in New York City, NY. LabCorp's presentation is planned for Thursday, March 3, 2011 at 8:00 a.m. (EST).
A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for rep... |
| | | 02/10/11 | Laboratory Corporation of America(R) Holdings Announces 2010 Fourth Quarter and Full Year Results| Revenue Growth Drives Q4 Adjusted EPS of $1.34, up 15.5%, and Operating Cash Flow of $259.2 Million
Board Authorizes New $500 Million Share Repurchase Program
BURLINGTON, N.C., Feb 10, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the quarter and year ended December 31, 2010. These results include the operations of Genzyme Genetics for the month of December.
Fourth Quarter Results
Net earnings were $131.8 million... |
| | | 01/31/11 | LabCorp publishes the Virology Report on its newly launched "Research" web page http://www.labcorp.com/research/virology| BURLINGTON, N.C., Jan 31, 2011 (BUSINESS WIRE) --Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE: LH) today released the Virology Report on its "Research"
web page, an unprecedented resource for scientists and healthcare
professionals. The Virology Report is the first in a series of reports
examining and analyzing the vast information collected from LabCorp's
clinical testing services. LabCorp and its virology Centers of
Excellence... |
| | | 01/05/11 | LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference| BURLINGTON, N.C., Jan 05, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp's presentation is planned for Wednesday, January 12, 2011 at 10:00 a.m. (PST).
A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for ... |
| | | 01/03/11 | Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021| BURLINGTON, N.C., Jan 03, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.
The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee) a... |
| |
|
Receive E-mail Alerts | 
RSS Feeds
